For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230413:nRSM1710Wa&default-theme=true
RNS Number : 1710W Faron Pharmaceuticals Oy 13 April 2023
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron to Present at Canaccord Horizons in Oncology Virtual Conference
Press release, April 13, 2023
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on tackling
cancers via immunotherapy, today announces that Chief Executive Officer, Dr.
Markku Jalkanen and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will
present at the Canaccord Genuity Horizons in Oncology Virtual Conference on
April 20 at 8 AM EST.
Faron will present on the panel, "Boosting checkpoint inhibitors - finally two
solutions?". Dr. Jalkanen and Dr. Fjällskog will discuss the most recent data
for bexmarilimab, the company's wholly owned immunotherapy asset, for treating
hematological malignancies and solid tumors.
For more information please contact:
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com (mailto:julia.balanova@faron.com)
investor.relations@faron.com (mailto:investor.relations@faron.com)
Phone: +1 (917) 306-6096
Media Contact
Faron Pharmaceuticals
Jennifer C. Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com (mailto:faron@consilium-comms.com)
Phone: +44 (0)20 3709 5700
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy with the
potential to provide immune stimulation for treatment-resistant cancers
through targeting myeloid cell function. A novel anti-CLEVER-1 humanised
antibody, bexmarilimab targets CLEVER-1 positive (Common Lymphatic Endothelial
and Vascular Endothelial Receptor 1) tumor-associated macrophages (TAMs) in
the tumor microenvironment, converting highly immunosuppressive M2 macrophages
to immune-stimulating M1 macrophages. As an immuno-oncology therapy,
bexmarilimab has therapeutic potential as a single-agent therapy or in
combination with other standard treatments including immune checkpoint
molecules in both solid tumors and hematologic malignancies.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) together with its
subsidiaries, is a clinical stage biopharmaceutical group focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation. Bexmarilimab, a novel anti-CLEVER-1 humanized
antibody, is its investigative precision immunotherapy with the potential to
provide permanent immune stimulation for difficult-to-treat cancers through
targeting myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with hematological cancers and untreatable
solid tumors, bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune checkpoint
molecules. In terms of other pipeline assets, Traumakine® is an
investigational intravenous (IV) interferon beta-1a therapy for the treatment
of hyperinflammatory conditions. Faron is headquartered in Turku, Finland.
Further information is available at www.faron.com (http://www.faron.com/) .
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRANKNBDPBKDDQD